Literature DB >> 11284449

P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin.

C Pauli-Magnus1, T Mürdter, A Godel, T Mettang, M Eichelbaum, U Klotz, M F Fromm.   

Abstract

Digoxin is a drug with a narrow therapeutic index, which is substrate of the ATP-dependent efflux pump P-glycoprotein. Increased or decreased digoxin plasma concentrations occur in humans due to inhibition or induction of this drug transporter in organs with excretory function such as small intestine, liver and kidneys. Whereas particle size, dissolution rate and lipophilic properties have been identified as determinants for absorption of digitalis glycosides, little is known about P-glycoprotein transport characteristics of digitalis glycosides such as digitoxin, alpha-methyldigoxin, beta-acetyldigoxin and ouabain. Using polarized P-glycoprotein-expressing cell lines we therefore studied whether these compounds are substrates of P-glycoprotein. Polarized transport of digitalis glycosides was assessed in P-glycoprotein-expressing Caco-2 and L-MDR1 cells (LLC-PK1 cells stably transfected with the human MDR1 P-glycoprotein). Inhibition of P-glycoprotein-mediated transport of these compounds in Caco-2 cells was determined using the cyclosporine analogue PSC-833 (valspodar) as inhibitor of P-glycoprotein. No polarized transport was observed for ouabain. However, basal-to-apical transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin was greater than apical-to-basal transport in Caco-2 and L-MDR1 cells. In Caco-2 cells net transport rates of these compounds were similar to those of digoxin (digoxin: 16.0+/-4.4%, digitoxin: 15.0+/-3.3%, beta-acetyldigoxin: 16.2+/-1.6%, alpha-methyldigoxin: 13.5+/-4.8%). Furthermore, polarized transport of these compounds could be completely inhibited by 1 microM PSC-833. In summary, these data provide evidence that not only digoxin, but also digitoxin, alpha-methyldigoxin and beta-acetyldigoxin are substrates of P-glycoprotein.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11284449     DOI: 10.1007/s002100000354

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  13 in total

Review 1.  [Drug interactions. Mechanisms and clinical relevance].

Authors:  U Klotz; W Beil; C Gleiter; B Drewelow; E Garbe; A Gillessen; E Mutschler
Journal:  Internist (Berl)       Date:  2003-11       Impact factor: 0.743

2.  Ouabain attenuates cardiotoxicity induced by other cardiac steroids.

Authors:  M Nesher; U Shpolansky; N Viola; M Dvela; N Buzaglo; H Cohen Ben-Ami; H Rosen; D Lichtstein
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

3.  Modification of the P-glycoprotein dependent pharmacokinetics of digoxin in rats by human recombinant interferon-alpha.

Authors:  Makrem Ben Reguiga; Laurence Bonhomme-Faivre; Simone Orbach-Arbouys; Robert Farinotti
Journal:  Pharm Res       Date:  2005-08-16       Impact factor: 4.200

Review 4.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

5.  Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein.

Authors:  Iouri Bachmakov; Sabine Rekersbrink; Ute Hofmann; Michel Eichelbaum; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-04-15       Impact factor: 3.000

6.  Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.

Authors:  Kari T Kivistö; Jörg Zukunft; Ute Hofmann; Mikko Niemi; Sabine Rekersbrink; Swetlana Schneider; Gerd Luippold; Matthias Schwab; Michel Eichelbaum; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

7.  Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies.

Authors:  Sonja Eberl; Bertold Renner; Antje Neubert; Mareike Reisig; Iouri Bachmakov; Jörg König; Frank Dörje; Thomas E Mürdter; Andreas Ackermann; Harald Dormann; Karl G Gassmann; Eckhart G Hahn; Stefanie Zierhut; Kay Brune; Martin F Fromm
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 8.  ABC of oral bioavailability: transporters as gatekeepers in the gut.

Authors:  C G Dietrich; A Geier; R P J Oude Elferink
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

Review 9.  Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy.

Authors:  Kathleen Köck; Markus Grube; Gabriele Jedlitschky; Lena Oevermann; Werner Siegmund; Christoph A Ritter; Heyo K Kroemer
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  The association of ABCB1 polymorphisms and elevated serum digitoxin concentrations in geriatric patients.

Authors:  Charalampos Dragonas; Jan T Wagner; Hans J Heppner; Thomas Bertsch; Wolfgang Muhlberg; Susanne Wicklein; Andreas Pahl; Christine Diewald; Iouri Bachmakov; Cornel C Sieber; Martin F Fromm
Journal:  Eur J Clin Pharmacol       Date:  2007-12-16       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.